The featured pharmaphorum article explores the challenges associated with long-term follow-up (LTFU) studies for cell & gene therapies (CAGT) and discusses requirements established by regulatory authorities such as the FDA and EMA, as well as the need for efficient, patient-centric data collection approaches that can adapt to evolving patient journeys, regulatory expectations and technological advancements.

Read the full article by clicking the DOWNLOAD button.

Contact us to learn how we can help bring your advanced therapy to market.